#United States #New York #Class Action #The Gross Law Firm #Sarepta Therapeutics

Important Notice for Sarepta Therapeutics Shareholders

The Gross Law Firm recently announced crucial information for shareholders of Sarepta Therapeutics, Inc. (NASDAQ:
SRPT). If you acquired shares during the specified period of June 22, 2023, to June 24, 2025, you may be eligible to participate in a class action lawsuit against the company. This legal action is essential for recovering potential losses stemming from alleged misleading practices by Sarepta Therapeutics.

Class Action Overview

Shareholders are encouraged to closely scrutinize the allegations stemming from the actions of Sarepta Therapeutics during the class period. The lawsuit claims that the company issued significant false or misleading statements about its gene therapy product, ELEVIDYS, which is intended for treating Duchenne Muscular Dystrophy. Key allegations include the following:
1. Safety Risks: It is alleged that ELEVIDYS poses substantial safety concerns that were not disclosed to investors.
2. Trial Issues: Reports indicate that the trial protocols did not adequately identify severe adverse effects associated with ELEVIDYS treatment.
3. Regulatory Scrutiny: The severity of reported adverse events allegedly led to the halting of patient recruitment and dosing in clinical trials, raising questions from regulatory bodies and increasing the risks concerning the ongoing and potential future approvals of the therapy.
4. Misleading Statements: As a result of the outlined issues, the lawsuit claims that the company's leadership materially misled shareholders with overly optimistic statements devoid of a reasonable basis.

Given these concerning allegations, shareholders who may have experienced financial losses due to the misleading information are urged to consider participation in this class action lawsuit.

Next Steps for Participants

To join the ongoing legal proceedings, shareholders must register their information, which will ensure they are enrolled in monitoring systems designed to provide updates during the life of the case. It’s vital to note that registering as a shareholder does not obligate one to be a lead plaintiff; however, the deadline for those interested in being appointed as lead plaintiff is August 25, 2025.

For those looking to move forward, registration can be completed easily by visiting The Gross Law Firm's website and submitting the necessary information. The process is straightforward, and there are no costs associated with participation.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationwide for its dedication to protecting the rights of investors. The firm specifically focuses on holding companies accountable for misleading practices that adversely affect shareholders. Their commitment to ethical business conduct aims to ensure offenders are brought to justice and that investors who incur losses due to deceitful actions are vindicated. The firm has successfully handled numerous class actions and is well-equipped to navigate the complexities of securities litigation.

For further inquiries or individual consultations, shareholders can reach out directly to The Gross Law Firm at:

• - Office Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Phone: (646) 453-8903
• - Email: [email protected]

Stay proactive and ensure your rights are protected as part of this essential class action suit. Join others in seeking justice against Sarepta Therapeutics to recover losses incurred from their actions.